Antipseudomonal penicillins

Introduction

Antipseudomonal penicillins are a subclass of extended-spectrum penicillins specifically designed to target Pseudomonas aeruginosa, a highly resistant Gram-negative pathogen commonly associated with hospital-acquired infections. They retain the general properties of β-lactam antibiotics but are chemically modified to enhance penetration into Gram-negative bacteria and improve activity against Pseudomonas and other resistant organisms.

Because Pseudomonas aeruginosa has multiple resistance mechanisms (efflux pumps, β-lactamases, porin channel changes), therapy often requires combination regimens or co-administration with β-lactamase inhibitors.

---

Classification and Generic Names

The main antipseudomonal penicillins include:

1. Carboxypenicillins

   • Ticarcillin

   • Carbenicillin (older, less commonly used)

2. Ureidopenicillins

   • Piperacillin

   • Mezlocillin (less widely available today)

   • Azlocillin (rarely used now)

These agents are frequently used in combination with β-lactamase inhibitors:

• Ticarcillin–clavulanate

• Piperacillin–tazobactam (widely used in clinical practice)

---

Mechanism of Action

Like all β-lactam antibiotics, antipseudomonal penicillins act by:

• Inhibiting penicillin-binding proteins (PBPs) involved in bacterial cell wall synthesis.

• Preventing peptidoglycan cross-linking, leading to weakened cell walls and eventual bacterial lysis.

They have bactericidal activity, particularly against Gram-negative organisms, but are vulnerable to hydrolysis by β-lactamases unless paired with an inhibitor.

---

Antimicrobial Spectrum

• Excellent activity: Pseudomonas aeruginosa, Enterobacteriaceae (e.g., E. coli, Klebsiella, Proteus, Enterobacter), Haemophilus influenzae.

• Good activity: Streptococcus species (excluding MRSA and resistant pneumococci), some anaerobes (especially with β-lactamase inhibitors).

• Limited activity: Staphylococcus aureus (only methicillin-sensitive strains).

• Not effective against: MRSA, atypical pathogens (Mycoplasma, Chlamydia, Legionella).

---

Clinical Uses

1. Severe Pseudomonas infections

• Hospital-acquired pneumonia (including ventilator-associated pneumonia).

• Bacteremia and sepsis due to Pseudomonas.

• Urinary tract infections caused by multidrug-resistant Gram-negative bacilli.

2. Intra-abdominal infections

• Peritonitis, appendicitis, and abscesses, especially with piperacillin–tazobactam.

3. Skin and soft tissue infections

• Diabetic foot infections, burns, and surgical wound infections where Pseudomonas is suspected.

4. Neutropenic fever (immunocompromised patients)

• Broad empiric coverage with piperacillin–tazobactam.

5. Mixed aerobic/anaerobic infections

• Intra-abdominal sepsis, gynecologic infections, and aspiration pneumonia (with β-lactamase inhibitor combinations).

---

Dosage Examples

• Piperacillin–tazobactam: 4.5 g IV every 6–8 hours (adjusted for renal function).

• Ticarcillin–clavulanate: 3.1 g IV every 6 hours.

• Carbenicillin: 1–2 g IV every 4–6 hours (historical, rarely used).

• Mezlocillin: 3–4 g IV every 6–8 hours (less common now).

Note: Doses vary with infection severity, renal clearance, and whether used in combination therapy. Extended or continuous infusion may be used in critically ill patients to optimize pharmacodynamics.

---

Contraindications

• Absolute: Hypersensitivity to penicillins (history of anaphylaxis).

• Relative:

  • Severe renal impairment (dose adjustment required).

  • Cross-allergy with cephalosporins or carbapenems.

  • History of severe β-lactam allergy (avoid or use with caution).

---

Adverse Effects

• Hypersensitivity reactions: Rash, urticaria, anaphylaxis.

• Gastrointestinal: Diarrhea, nausea, risk of Clostridioides difficile infection.

• Hematologic: Neutropenia, thrombocytopenia with prolonged use.

• Hepatic: Elevated liver enzymes, cholestatic jaundice (rare).

• Renal: Interstitial nephritis, high sodium load (especially with carbenicillin and ticarcillin) can exacerbate heart failure.

• Neurological: Seizures (especially in high doses or renal failure).

• Electrolyte disturbances: Hypokalemia, hypernatremia (due to sodium salts of carboxypenicillins).

---

Precautions

• Renal impairment: Dose adjustment required to avoid neurotoxicity.

• Electrolyte balance: Monitor sodium and potassium, especially in critically ill or cardiac patients.

• Hematologic monitoring: CBC in prolonged therapy.

• Liver function: Periodic monitoring with long-term use of piperacillin–tazobactam.

• Allergy history: Always screen for previous β-lactam reactions.

---

Drug Interactions

• Aminoglycosides: Sometimes co-administered for synergy against Pseudomonas, but in vitro inactivation can occur if mixed in the same IV solution. Administer separately.

• Anticoagulants (e.g., warfarin, heparin): Piperacillin may alter platelet function, increasing bleeding risk.

• Methotrexate: Reduced clearance → increased toxicity.

• Probenecid: Inhibits renal excretion of penicillins, prolonging half-life.

• Vancomycin: Increased risk of nephrotoxicity when combined.

---

Resistance Considerations

Pseudomonas aeruginosa can develop resistance via:

• Production of β-lactamases (AmpC, extended-spectrum β-lactamases, carbapenemases).

• Efflux pumps reducing intracellular antibiotic concentration.

• Altered porin channels preventing entry.

• Mutations in PBPs reducing binding affinity.

Therefore, therapy often involves piperacillin–tazobactam or use in combination with aminoglycosides, fluoroquinolones, or carbapenems depending on susceptibility.

---

Comparative Overview

• Carbenicillin: First antipseudomonal penicillin; largely replaced due to sodium load and inferior efficacy.

• Ticarcillin: More potent than carbenicillin, but largely replaced by piperacillin.

• Piperacillin: Most widely used; superior activity against Pseudomonas and Enterobacteriaceae.

• Piperacillin–tazobactam: Gold standard broad-spectrum choice for severe hospital-acquired infections.

---

Clinical Significance

Antipseudomonal penicillins are vital in empiric therapy for life-threatening Gram-negative infections, especially in immunocompromised and critically ill patients. Despite resistance challenges, piperacillin–tazobactam remains a cornerstone in ICU settings.

The rational use of these antibiotics with antimicrobial stewardship is essential to prevent resistance development and preserve their clinical utility.